跳至主要内容
临床试验/JPRN-UMIN000016966
JPRN-UMIN000016966已完成未知

Study of the clinical utility and safety in combination use of the GLI-1 analogue and Insulin degludec in type 2 diabetic patients. - Study of the clinical utility and safety in combination use of the GLI-1 analogue and Insulin degludec in type 2 diabetic patients.

Division of Nephrology, Endocrinology and Metabolism, Department of Internal Medicine, Tokai University School of Medicine0 个研究点目标入组 30 人开始时间: 2015年3月30日最近更新:

试验速览

阶段
未知
状态
已完成
发起方
入组人数
30

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 80years-old(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1)Patients with advanced diabetic complications. 2)Patients with to the contraindication of GLP-1 receptor agonist (Victoza subcutaneous injection18mg) (Liraglutide) 3)Patients with to the contraindication of the long acting insulin analog formulation (Tresiba Injection) (Degludec) 4)Patients judged by the investigator to be ineligible for some other reason

研究者

发起方
Division of Nephrology, Endocrinology and Metabolism, Department of Internal Medicine, Tokai University School of Medicine

相似试验

Study of the clinical utility and safety in... | 临床试验